ArticlePsychiatry investigation2026
Peripartum Magnesium Sulfate and Post-Delivery Depression: A Nationwide Cohort Study With 13-Year Follow-Up.
Article in Psychiatry investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough its potential antidepressant effects have been suggested, evidence on long-term outcomes for post-delivery depression remains limited. We evaluated whether peripartum intravenous magnesium sulfate (MgSO₄) is associated with a reduced risk of postpartum depression (PPD) within 12 months and its long-term trajectory over 13 years.
methodsThis nationwide retrospective cohort study included all women in South Korea who delivered between 2010 and 2014, excluding those with prior depression. Exposure was defined as intravenous MgSO₄ administration during delivery hospitalization. Propensity score (PS) matching (1:5) was used to balance baseline characteristics. We employed Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for both 12-month PPD and long-term depression (up to 13 years).
resultsAmong 1,583,253 eligible mothers, 9,756 (0.6%) received MgSO₄. In the PS-matched cohort (9,682 exposed; 35,140 unexposed), there was no significant association between MgSO₄ and the primary outcome of 12-month PPD (HR, 1.11; 95% CI, 0.97-1.26; p=0.114). Similarly, the risk of long-term post-delivery depression showed no significant difference (HR, 1.02; 95% CI, 0.97-1.07; p=0.388). These findings were consistent in the dose-response analysis for 12-month PPD (HR, 1.10 per 10 g increase; 95% CI, 0.96- 1.24; p=0.144) and in subgroup analyses stratified by preeclampsia status.
conclusionPeripartum MgSO₄ exposure was not associated with a reduced risk of either 12-month PPD or long-term post-delivery depression. Despite its biological plausibility, routine obstetric use of MgSO₄ does not appear to confer preventive mental health benefits for mothers in the general obstetric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.